ReviewLife sciences2020
SARS-CoV-2 and coagulation disorders in different organs.
Review in Life sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 138 citations in OpenAlex.
- Early Placental Angioactive Response to Maternal SARS-CoV-2 Infection: an Immunohistochemical Study.Reproductive sciences (Thousand Oaks, Calif.) · 2026Article
- Long COVID and the kidney.Nature reviews. Nephrology · 2025Review
- Mathematical modeling and analysis of COVID-19 and typhoid fever co-dynamics with treatment.Scientific reports · 2025Article
- Glucose transporter 1 is essential to maintain brain endothelial cell homeostasis under hyperglycemia condition.American journal of physiology. Cell physiology · 2025Article
- Article
- Green Tea: Current Knowledge and Issues.Foods (Basel, Switzerland) · 2025Review
- Establishing a prediction model for lower extremity deep venous thrombosis in emergency inpatients in the post epidemic era.Frontiers in surgery · 2025Article
- Article
- Combination of spatial transcriptomics analysis and retrospective study reveals liver infection of SARS-COV-2 is associated with clinical outcomes of COVID-19.EBioMedicine · 2025Article
- The COVID-19 thrombus: distinguishing pathological, mechanistic, and phenotypic features and management.Journal of thrombosis and thrombolysis · 2025Review
- The Potential of Glucosinolates and Their Hydrolysis Products as Inhibitors of Cytokine Storms.Molecules (Basel, Switzerland) · 2024Review
- Systems-wide view of host-pathogen interactions across COVID-19 severities using integrated omics analysis.iScience · 2024Article
- AC-73 and Syrosingopine Inhibit SARS-CoV-2 Entry into Megakaryocytes by Targeting CD147 and MCT4.Viruses · 2024Article
- Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19.Life science alliance · 2023Article
- Venovenous extracorporeal membrane oxygenation for COVID-19 and influenza H1N1 associated acute respiratory distress syndrome: A comparative cohort study in China.Journal of intensive medicine · 2023Article
- Coagulation biomarkers and coronavirus disease 2019 phenotyping: a prospective cohort study.Thrombosis journal · 2023Article
- Review
- A Literature Review on SARS-CoV-2 and Other Viruses in Thyroid Disorders: Environmental Triggers or No-Guilty Bystanders?International journal of environmental research and public health · 2023Review
- Saddle pulmonary embolism in the setting of COVID-19 infection: A systematic review of case reports and case series.Open medicine (Warsaw, Poland) · 2023Review
- α1-Adrenergic Stimulation Increases Platelet Adhesion to Endothelial Cells Mediated by TRPC6.Advances in experimental medicine and biology · 2023Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) is a prominent pandemic disease that emerged in China and hurriedly stretched worldwide. There are many reports on COVID-19 associated with the amplified incidence of thrombotic events. In this review, we focused on COVID-19 coupled with the coagulopathy contributes to severe outcome inclusive of comorbidities such as venous thromboembolism, stroke, diabetes, lung, heart attack, AKI, and liver injury. Initially, the COVID-19 patient associated coagulation disorders show an elevated level of the D-dimer, fibrinogen, and less lymphocyte count such as lymphopenia. COVID-19 associated with the Kawasaki disease has acute vasculitis in childhood which further affects the vessels found all over the body. COVID-19 linked with the thrombotic microangiopathy triggers the multiple vasculitis along with the arterioles thrombosis, medium, large venous and arterial vessels mediates the disseminated intravascular coagulation (DIC). SARS-Co-V-2 patients have reduced primary platelet production, increased destruction of the platelet, decreased circulating platelet leads to the condition of increased thrombocytopenia which contributes to the coagulation disorder. Endothelial dysfunction plays an important role in the coagulation disorders via increased generation of the thrombin and stops fibrinolysis further leads to hypercoagulopathy. Along with that endothelial dysfunction activates the complement system pathways and contributes to the acute and chronic inflammation via cytokine storm with the production of the cytokines and chemokines, coagulation in different organs such as lung, brain, liver, heart, kidney and further leads to multi-organ failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.